PHARMOSA BIOPHARM INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.5 TWD | -0.71% |
|
-9.27% | -21.02% |
| 15/05 | Pharmosa Biopharm Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 28/03 | Pharmosa Biopharm Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | 314.5 10.12K 26.23K | Capitalization | 10.31B 332B 860B |
|---|---|---|---|---|---|
| Net income 2022 | -267M -8.59B -22.27B | Net income 2023 | 8M 257M 667M | EV / Sales 2022 | - |
| Net cash position 2022 | 651M 20.95B 54.33B | Net cash position 2023 | 830M 26.69B 69.21B | EV / Sales 2023 | 3,01,56,637 x |
| P/E ratio 2022 |
-23.5
x | P/E ratio 2023 |
1,257
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.54% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.71% | ||
| 1 week | -9.27% | ||
| Current month | -9.03% | ||
| 3 months | -29.37% | ||
| 6 months | -22.26% | ||
| Current year | -21.02% |
1 week
69.20
78.00
1 month
69.0082.70
Current year
64.10125.50
1 year
64.10162.00
3 years
31.00162.00
5 years
31.00162.00
10 years
31.00162.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pei Kan
CEO | Chief Executive Officer | - | 01/18/01 |
Shu Ping Yang
DFI | Director of Finance/CFO | - | 01/15/01 |
Ko Chieh Chen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Jen Wu
BRD | Director/Board Member | - | 10/22/10 |
Ko Jui Shih
BRD | Director/Board Member | - | 25/21/25 |
Wen Chang Chang
BRD | Director/Board Member | - | 10/22/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/24/12 | 69.5 | -0.71% | 121 555 |
| 11/24/11 | 70 | -3.71% | 319,880 |
| 07/24/07 | 72.7 | -1.36% | 211,752 |
| 06/24/06 | 73.7 | -4.78% | 376,732 |
| 05/24/05 | 77.4 | +1.04% | 151,498 |
End-of-day quote Taipei Exchange, June 12, 2024
More quotes
Pharmosa Biopharm Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The main products include L606, for the treatment of Category I pulmonary arterial hypertension (PAH); L606, for the treatment of Category III pulmonary hypertension caused by interstitial lung disease (PH-ILD); L606, for the treatment of chronic thromboembolic Category IV pulmonary hypertension (CTEPH); L608, for the treatment of Category I pulmonary arterial hypertension (PAH).
| 1st Jan change | Capi. | |
|---|---|---|
| -21.02% | 279M | |
| +50.19% | 56.87B | |
| +37.15% | 39.72B | |
| -5.83% | 39.27B | |
| -6.90% | 28.73B | |
| +13.24% | 26.21B | |
| -15.57% | 19.79B | |
| +32.15% | 12.28B | |
| +27.87% | 12.23B | |
| +0.60% | 12.12B |
- Stock Market
- Equities
- 6875 Stock
